Search clinical trials for: Rotigotine PR2.2.1

Total 91 results

UCB Pharma SA

Completed

Single-site, Open-label, Randomized, Cross-over Study in Healthy Chinese Subjects to Evaluate the Bioequivalence of Single-dose Rotigotine Transdermal Patch Comparing 2 Different Formulations

Healthy

China
UCB Pharma
Otsuka Pharmaceutical Co., Ltd.

Completed

Bioequivalence Study of Rotigotine Transdermal Patch With Two Different Formulations in Healthy Japanese Subjects

Healthy Volunteers

Germany
UCB Biopharma SRL

Terminated

A Follow-up Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome

Restless Legs Syndrome

United States
UCB Pharma

Completed

Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine Transdermal Patch in Healthy Chinese Subjects

Healthy

China
I.R.C.C.S. Fondazione Santa Lucia

Completed

Effects of Dopaminergic Therapy in Patients With Alzheimer's Disease (DOPAD)

Alzheimer Disease

Italy
UCB BIOSCIENCES GmbH

Completed

Study to Evaluate the Pharmacokinetics, Safety, Tolerability of Repeated Dose Transdermal Rotigotine in Japanese and Caucasian Subjects

Healthy

Germany
UCB BIOSCIENCES GmbH
Pharmaceutical Health Sciences; Bracket Global

Completed

A Study to Compare the Adhesiveness of 2 Different Rotigotine Patches Used for the Treatment of Parkinson's Disease

Parkinson's Disease

Germany
I.R.C.C.S. Fondazione Santa Lucia
Alzheimer's Drug Discovery Foundation

Active, not recruiting

Dopaminergic Therapy for Frontotemporal Dementia Patients

Mental Disorders | Brain Diseases | Central Nervous System Diseases | Nervous System Diseases | Neurologic Manifestations | Neurobehavioral Manifestations | Neurocognitive Disorders | Neurodegenerative Diseases | TDP-43 Proteinopathies | Proteostasis Deficiencies | Dementia | Language Disorders | Communication... and other conditions

Italy
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-Term Extension Trial From Late Phase II of SPM 962 in Patients With Restless Legs Syndrome (RLS)

Idiopathic Restless Legs Syndrome
Otsuka Pharmaceutical Co., Ltd.

Completed

A Dose-ranging Study for SPM 962 in Parkinson's Disease Patients

Parkinson's Disease

Japan
UCB Pharma

Completed

Study to Compare Adhesiveness of Two Different Rotigotine Patch Formulations

Parkinson's Disease

Germany, Austria, United Kingdom
Luye Pharma Group Ltd.

Completed

Pharmacokinetic Study of LY03003 in Patients With Parkinson's Disease

Parkinson Disease

United States
Serina Therapeutics

Active, not recruiting

A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214

Parkinson's Disease

United States
UCB Biopharma SRL

Terminated

A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown Cause

Restless Legs Syndrome

United States
Inflamax Research Incorporated

Completed

Irritation and Sensitization Potential of Repeat Applications of Rotigotine Patch

Bioequivalence - Irritation and Sensitization Potential of Transdermal Patch

United States, Canada
UCB BIOSCIENCES GmbH
Schwarz BioSciences GmbH; Alfred-Nobel-Str. 10; 40789 Monheim am Rhein

Completed

Study to Evaluate the Pharmacokinetics (PK), Safety, Tolerability of Single-Dose Transdermal Rotigotine in Japanese and Caucasian Healthy Male / Female Subjects

Healthy

Germany
Sandoz

Terminated

An Open, Randomised, Single Dose, 2-period, 2-sequence Crossover Adhesion Study of Two Different Transdermal Patches Containing Rotigotine.

Parkinson Disease

Germany
Otsuka Pharmaceutical Co., Ltd.

Completed

A Placebo-Controlled Study for SPM 962 in Restless Legs Syndrome (RLS) Patients

Idiopathic Restless Legs Syndrome

Japan
UCB Pharma

Completed

Study in Healthy Volunteers to Prove That Two Different Formulations of Rotigotine Patches Deliver Equivalent Drug Amount to the Body

Healthy Volunteers

Germany
SocraTec R&D GmbH
Luye Pharma Group Ltd.; SocraMetrics GmbH

Completed

Clinical Trial to Investigate Patch Adhesion of Rotigotine Containing Patches in Patients With Parkinson's Disease

Parkinson Disease

Germany
Luye Pharma Group Ltd.

Completed

Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease

Parkinson's Disease

United States
UCB Pharma

Completed

Named Patient Program With Rotigotine Transdermal System

Conditions for Which There is a Documented Medical Necessity to Receive Treatment With Rotigotine

United States
Peking University Third Hospital

Completed

Efficacy and Safety of Rotigotine in the Treatment of Patients With Early Stage of Primary Parkinson's Disease

Parkinson's Disease

China
UCB Pharma

Completed

Study in Healthy Volunteers to Prove That 2 Rotigotine Patches From Different Manufacturing Processes Deliver Equivalent Drug Amount to the Body.

Healthy

Germany
UCB Pharma

Completed

Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of Parkinson Symptoms

Parkinson's Disease
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease Patients

Parkinson's Disease

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease Patients

Parkinson's Disease

Japan
Luye Pharma Group Ltd.
Beijing Bozhiyin T&S Co., Ltd.

Completed

A Study of LY03003 in Patients With Early-stage Parkinson's Disease

Parkinson Disease
Luye Pharma Group Ltd.
Parexel

Completed

A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD

Parkinson Disease

China
Johns Hopkins University
National Institute on Aging (NIA)

Terminated

Anxiety in Parkinson's: Use of Quantitative Methods to Guide Rational Treatment (ANXPD)

Parkinson Disease | Anxiety Disorders

United States
UCB Pharma

Completed

Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of RLS Symptoms

Restless Legs Syndrome

Germany
Virginia Commonwealth University
National Institute on Drug Abuse (NIDA)

Recruiting

Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder

Substance-Related Disorders

United States
UCB Pharma

Completed

Study in Healthy Volunteers to Prove That Two Rotigotine Patches From Different Manufacturing Sites Deliver Equivalent Drug Amount to the Body

Healthy Volunteers

Germany
University Hospital, Montpellier

Completed

Effect of Rotigotine Patch Treatment on Cardiovascular Markers in Idiopathic Restless Legs Syndrome

Restless Legs Syndrome (RLS)

France
Luye Pharma Group Ltd.
Beijing Bozhiyin T&S Co., Ltd.

Completed

A Multiple Ascending Dose Study With LY03003 in Patients With Early-stage Parkinson's Disease

Parkinson Disease

China
East Carolina University

Unknown

Study to Assess Dopamine Receptor Modulation With Rotigotine to Enhance Morphine Analgesia in the Dental Model

Post-op Pain

United States
Luye Pharma Group Ltd.

Completed

A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers

Parkinson Disease

United States
University Hospital, Rouen

Not yet recruiting

Safety of RotigotiNe in Patients With Autosomal Dominant Polycystic Kidney Disease (ETERNAL-PKD)

Kidney Diseases
UCB Pharma

Completed

An Extension Trial to Investigate Long-Term Treatment With Transdermal Rotigotine in Idiopathic Restless Legs Syndrome

Restless Legs Syndrome

United States
UCB Pharma

Completed

An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease

Idiopathic Parkinson's Disease

United States, Germany, Spain, Austria, Israel, Italy, South Africa, United Kingdom
UCB BIOSCIENCES, Inc.

Completed

Long-Term Follow-Up Study for Safety, Efficacy and Tolerability of Rotigotine in Adolescents With Restless Legs Syndrome

Restless Legs Syndrome

United States
UCB Pharma

Completed

Phase 3 Open-label Extension Trial With Rotigotine in Idiopathic Restless Legs Syndrome Subjects

Idiopathic Restless Legs Syndrome

Germany
UCB Pharma

Completed

Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch

Parkinson's Disease

United States, Chile, Mexico, India, Peru
UCB Pharma

Terminated

Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease

Parkinson's Disease

Spain, South Africa, New Zealand, Hungary, United States, Germany, Italy, Australia, Finland, United Kingdom, Poland
UCB Pharma

Completed

Trial to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine in Healthy Korean Subjects

Parkinson's Disease

Korea, Republic of
UCB Pharma

Completed

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease

Early Stage Parkinson's Disease

Poland, United Kingdom, Germany, Spain, Switzerland, Belgium, South Africa, New Zealand, Czech Republic, Austria, Hungary, Australia, Italy, Israel, Sweden, Norway, Croatia, Netherlands, Finland, France
UCB BIOSCIENCES GmbH

Completed

Effects of Neupro on Cardiovascular Observations in Patients With Restless Legs Syndrome (ENCORE)

Restless Legs Syndrome

Germany
University College, London
Medical Research Council

Completed

Dopamine Agonist for Hemispatial Neglect and Motor Deficit Post Stroke

Hemispatial Neglect | Motor Deficit | Right Hemisphere Stroke

United Kingdom
UCB BIOSCIENCES, Inc.

Completed

Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome

Restless Legs Syndrome

United States
UCB Pharma

Completed

Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome

Restless Legs Syndrome

United States

3

Subscribe